Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 ...

Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Apellis Pharmaceuticals, Inc. ( APLS) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM EST ...
sharewise

Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y

Apellis Pharmaceuticals APLS reported fourth-quarter 2025 loss of 47 cents per share, wider than the Zacks Consensus Estimate ...

Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf.

Apellis Pharmaceuticals (NASDAQ:APLS) executives outlined a three-part strategy for the company at TD Cowen’s 46th Annual Healthcare Conference, emphasizing a “durable and resilient” SYFOVRE franchise ...

C3.ai outlines $135M cost reduction plan and 26% headcount cut amid strategic reset

Q3 FY2026 earnings call recap: weak sales, major restructuring (26% headcount cut), federal bookings strength, and FY guidance.

Akebia Therapeutics Q4 Earnings Call Highlights

Akebia Therapeutics (NASDAQ:AKBA) executives used the company’s fourth-quarter 2025 earnings call to review the first full year of Vafseo’s U.S. launch, discuss efforts to build clinical and economic ...
BMJ Case Reports

When haematuria is more than warfarin: lambda-predominant IgA nephropathy

A woman in her 20s with a mechanical mitral valve replacement on long-term warfarin therapy presented with frank haematuria and acute kidney injury (AKI). The initial clinical impression was ...